Carregant...
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
OBJECTIVES: Examine the probability of new active substances (NASs) approved in Canada between 1 January 1997 and 31 March 2012 acquiring a serious postmarket safety warning. DESIGN: Cohort study. DATA SOURCES: Annual reports of the Therapeutic Products Directorate and the Biologic and Genetic Thera...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3931983/ https://ncbi.nlm.nih.gov/pubmed/24549164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2013-004289 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|